Literature DB >> 16508002

Regulation and role of Raf-1/B-Raf heterodimerization.

Linda K Rushworth1, Alison D Hindley, Eric O'Neill, Walter Kolch.   

Abstract

The Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway participates in the control of many fundamental cellular processes including proliferation, survival, and differentiation. The pathway is deregulated in up to 30% of human cancers, often due to mutations in Ras and the B-Raf isoform. Raf-1 and B-Raf can form heterodimers, and this may be important for cellular transformation. Here, we have analyzed the biochemical and biological properties of Raf-1/B-Raf heterodimers. Isolated Raf-1/B-Raf heterodimers possessed a highly increased kinase activity compared to the respective homodimers or monomers. Heterodimers between wild-type Raf-1 and B-Raf mutants with low or no kinase activity still displayed elevated kinase activity, as did heterodimers between wild-type B-Raf and kinase-negative Raf-1. In contrast, heterodimers containing both kinase-negative Raf-1 and kinase-negative B-Raf were completely inactive, suggesting that the kinase activity of the heterodimer specifically originates from Raf and that either kinase-competent Raf isoform is sufficient to confer high catalytic activity to the heterodimer. In cell lines, Raf-1/B-Raf heterodimers were found at low levels. Heterodimerization was enhanced by 14-3-3 proteins and by mitogens independently of ERK. However, ERK-induced phosphorylation of B-Raf on T753 promoted the disassembly of Raf heterodimers, and the mutation of T753 prolonged growth factor-induced heterodimerization. The B-Raf T753A mutant enhanced differentiation of PC12 cells, which was previously shown to be dependent on sustained ERK signaling. Fine mapping of the interaction sites by peptide arrays suggested a complex mode of interaction involving multiple contact sites with a main Raf-1 binding site in B-Raf encompassing T753. In summary, our data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiological activation process and that the heterodimer has distinct biochemical properties that may be important for the regulation of some biological processes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16508002      PMCID: PMC1430271          DOI: 10.1128/MCB.26.6.2262-2272.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  43 in total

1.  Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells.

Authors:  S Kao ; R K Jaiswal; W Kolch; G E Landreth
Journal:  J Biol Chem       Date:  2001-03-13       Impact factor: 5.157

2.  Positive and negative regulation of Raf kinase activity and function by phosphorylation.

Authors:  H Chong; J Lee; K L Guan
Journal:  EMBO J       Date:  2001-07-16       Impact factor: 11.598

3.  Active Ras induces heterodimerization of cRaf and BRaf.

Authors:  C K Weber; J R Slupsky; H A Kalmes; U R Rapp
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation.

Authors:  D Abraham; K Podar; M Pacher; M Kubicek; N Welzel; B A Hemmings; S M Dilworth; H Mischak; W Kolch; M Baccarini
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Involvement of B-Raf in Ras-induced Raf-1 activation.

Authors:  S Mizutani; K Inouye; H Koide; Y Kaziro
Journal:  FEBS Lett       Date:  2001-11-02       Impact factor: 4.124

6.  MEK kinase activity is not necessary for Raf-1 function.

Authors:  M Hüser; J Luckett; A Chiloeches; K Mercer; M Iwobi; S Giblett; X M Sun; J Brown; R Marais; C Pritchard
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

7.  Regulation of Raf-1 activation and signalling by dephosphorylation.

Authors:  Amardeep S Dhillon; Sharon Meikle; Zihni Yazici; Manfred Eulitz; Walter Kolch
Journal:  EMBO J       Date:  2002-01-15       Impact factor: 11.598

Review 8.  Signaling pathways for PC12 cell differentiation: making the right connections.

Authors:  D Vaudry; P J S Stork; P Lazarovici; L E Eiden
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

9.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

Review 10.  Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases.

Authors:  Alison Hindley; Walter Kolch
Journal:  J Cell Sci       Date:  2002-04-15       Impact factor: 5.285

View more
  162 in total

Review 1.  Catalytic mechanisms and regulation of protein kinases.

Authors:  Zhihong Wang; Philip A Cole
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

Review 2.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

Review 3.  Mechanistic principles of RAF kinase signaling.

Authors:  Christian M Udell; Thanashan Rajakulendran; Frank Sicheri; Marc Therrien
Journal:  Cell Mol Life Sci       Date:  2010-09-06       Impact factor: 9.261

4.  Nek10 mediates G2/M cell cycle arrest and MEK autoactivation in response to UV irradiation.

Authors:  Larissa S Moniz; Vuk Stambolic
Journal:  Mol Cell Biol       Date:  2010-10-18       Impact factor: 4.272

5.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

6.  Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.

Authors:  Elda Grabocka; Yuliya Pylayeva-Gupta; Mathew J K Jones; Veronica Lubkov; Eyoel Yemanaberhan; Laura Taylor; Hao Hsuan Jeng; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2014-02-10       Impact factor: 31.743

7.  Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Authors:  Che-Hung Shen; Ping Yuan; Rolando Perez-Lorenzo; Yaqing Zhang; Sze Xian Lee; Yang Ou; John M Asara; Lewis C Cantley; Bin Zheng
Journal:  Mol Cell       Date:  2013-10-03       Impact factor: 17.970

8.  Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms.

Authors:  Isabelle Hmitou; Sabine Druillennec; Agathe Valluet; Carole Peyssonnaux; Alain Eychène
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

9.  Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation.

Authors:  Michael Grasso; Michelle A Estrada; Christian Ventocilla; Minu Samanta; Jasna Maksimoska; Jessie Villanueva; Jeffrey D Winkler; Ronen Marmorstein
Journal:  ACS Chem Biol       Date:  2016-09-06       Impact factor: 5.100

10.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.